Standard Dental Labs Inc.: Investor Education Series — Part 2




Standard Dental Labs Inc.: Investor Education Series — Part 2

From Workbench to Workflow: Digitizing Craftsmanship at Scale

Digitizing craftsmanship—at scale.

ORLANDO, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) — Standard Dental Labs Inc. (OTCQB: TUTH) today published Part 2 of its Investor Education Series, focusing on how SDL’s operating model turns independent lab craftsmanship into a unified, technology-enabled workflow. The Company’s approach standardizes intake, production, and quality control across acquired labs, then channels volume through regional hubs to lower unit costs, improve turnaround times, and elevate consistency.

Part 2 details the integration roadmap, key operational KPIs, and the company’s people-first training strategy that scales artisan skill with modern tools.

“We’re not replacing artisans—we’re amplifying them,” said James Brooks, CEO of Standard Dental Labs. “A common digital backbone and SOPs let technicians do their best work faster, with fewer remakes and more predictable quality.”

Operational Pillars

• Digital intake: standardized case submission with support for intraoral scans; unified case management and tracking.
• SOPs & quality system: shared workflows, calibrated materials/equipment, documented QC checkpoints, and remake analytics.
• Regional hubs: consolidate high-throughput steps (milling/printing, finishing) to reduce overhead and turn-time variability.
• Centralized procurement: scale purchasing of alloys, ceramics, and logistics to expand gross margin.
• Secure data & compliance: HIPAA-aware handling of digital impressions and patient identifiers; vendor vetting and audit trails.

90‑Day Integration Playbook (Per Acquisition)

• Days 0–30: stabilize operations, map caseflow, preserve key client relationships, and align pricing/catalogs.
• Days 31–60: deploy digital tools, SOPs, and training; centralize select steps to pilot hub routing.
• Days 61–90: full SOP adoption, hub throughput ramp, and margin/cycle-time reporting to the roll-up dashboard.

KPI Dashboard for Shareholders

• Turnaround time (TAT) and on‑time delivery rate.
• Remake rate (by product line) and causes addressed.
• Gross margin expansion (materials, freight, labor leverage).
• Digital share of cases (intraoral-scanner adoption and CAD/CAM throughput).
• Technician productivity per shift and training completion.

Customer Value Proposition

• For clinicians: reliable quality, faster turns, single-standard experience across locations, and support for digital impressions.
• For lab owners joining SDL: liquidity plus access to better tools, training, and shared services; preserved local relationships.

Series Navigation

Previously in this series → Part 1: The Roll-Up Flywheel. Next up → Part 3: Capital to Catalysts. All parts: https://sdl.care/investors.

About Standard Dental Labs Inc.

Standard Dental Labs Inc. (OTCQB: TUTH) is a dental laboratory consolidator focused on acquiring and integrating privately owned labs to create a leading, technology-enabled network delivering crowns, bridges, dentures, and related prosthetics to dental professionals. By combining localized craftsmanship with platform scale, SDL aims to be the partner of choice for lab owners and clinicians. Website: https://sdl.care.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding potential acquisitions (including LOIs), the acquisition pipeline, the likelihood and timing of definitive agreements and closings, expected financial impact of completed acquisitions, revenue run-rate targets, integration plans, operational efficiencies, capital availability, and the Company’s growth strategy. Forward-looking statements are based on current expectations and involve inherent risks and uncertainties that could cause actual results to differ materially.

These risks include, but are not limited to, outcomes of due diligence; the ability to negotiate and execute definitive agreements on favorable terms, or at all; the availability of financing for acquisitions; the ability to successfully integrate acquired businesses and realize anticipated synergies; market competition; and other risks and uncertainties described in the Company’s filings, including its Form 1-A/A and related amendments filed with the U.S. Securities and Exchange Commission and disclosures furnished to OTC Markets. Standard Dental Labs Inc. undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor & Media Contact

Standard Dental Labs Inc.
424 E Central Blvd, Suite 308, Orlando, FL 32801
Phone: (407) 789-1923 • Email: info@sdl.care • Investors: https://sdl.care/investors
SOURCE: Standard Dental Labs Inc.

Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025




Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany.

With over 5,000 exhibitors from 70 countries and 80,000 visitors expected, MEDICA continues to serve as a pioneering international platform for innovation, communication, and business development across the entire medical technology value chain. The event consistently sets trends for the future of global healthcare.

Bringing together healthcare experts, industry leaders, policymakers, and commercial decision-makers, MEDICA features an extensive program of high-level forums, conferences, and special exhibitions.
The event provides an excellent opportunity to exchange insights, explore collaborations, and strengthen relationships with key opinion leaders shaping the future of cancer prevention and molecular diagnostics.

Mainz Biomed will present its current flagship product, ColoAlert®, a molecular stool-based screening test for the early detection of colorectal cancer, as well as further upcoming diagnostic solutions for early-stage cancer diagnosis. Attendees are invited to visit the Company at the joint booth of Rhineland-Pfalz, located in Hall 3, E92.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples.

To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, please contact ir@mainzbiomed.com

Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Evaxion announce 2026 financial calendar




Evaxion announce 2026 financial calendar

COPENHAGEN, Denmark, November 12, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its financial calendar for 2026 as summarized below:

March 5, 2026: Business update and full year 2025 financial results

April 16, 2026: Annual General Meeting

May 7, 2026: Business update and first quarter 2026 financial results

August 20, 2026: Business update and second quarter 2026 financial results

November 19, 2026: Business update and third quarter 2026 financial results

The financial calendar can also be found on our website.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City




Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City

TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will attend the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum to be held on November 20, 2025, in New York, NY.

Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc., will be available for one-on-one meetings with investors; to schedule a meeting, please contact your CG sale representative to set up a meeting with management.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

Beacon Therapeutics to Participate in the Jefferies Global Healthcare Conference




Beacon Therapeutics to Participate in the Jefferies Global Healthcare Conference

LONDON and CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London, UK.

The Company completed enrollment in its pivotal VISTA trial evaluating lead ocular gene therapy candidate, laru-zova, for the treatment of X-linked retinitis pigmentosa (XLRP) in July 2025 and expects twelve-month topline data in the second half of 2026.

About Beacon Therapeutics
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The Company is harnessing the transformative power of gene therapy to deliver the most meaningful outcomes for severe ocular diseases. Beacon’s pipeline currently targets devastating blinding retinal diseases such as X-linked retinitis pigmentosa (XLRP) and geographic atrophy.

Beacon Therapeutics’ investors include Forbion, Syncona Limited, Oxford Science Enterprises, TCGX and Advent Life Sciences, among others. Learn more about Beacon Therapeutics at beacontx.com and follow on LinkedIn for more updates.

Contact:
info@beacontx.com

Media & Investors:
beacon@icrhealthcare.com

LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer




LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer.

Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands.

“We are very pleased to welcome Kaya to LB Pharmaceuticals,” said Heather Turner, Chief Executive Officer. “Her deep experience leading neuroscience brands and preparing multiple successful launches will be instrumental as we advance LB-102 toward registration and commercialization. Kaya’s proven ability to translate science into patient and market impact will be key to maximizing the potential of LB-102 and driving long-term value creation.”

Before joining LB Pharmaceuticals, Ms. Pai Panandiker served as Chief Commercial Officer at Neumora Therapeutics, a clinical-stage biopharmaceutical company pioneering precision medicines for brain diseases. Previously, she was Head of Commercial at Cerevel Therapeutics, which was acquired by AbbVie in 2024, and General Manager, Neuroscience at Lundbeck U.S., where she oversaw the U.S. launches of REXULTI^® and TRINTELLIX^®, and the bipolar indication for ABILIFY MAINTENA^®, achieving blockbuster sales across the neuropsychiatry portfolio.

“It’s an exciting time to join LB Pharmaceuticals as we prepare to advance a differentiated therapy for schizophrenia and bipolar depression, with potential to benefit patients across a broader range of neuropsychiatric disorders,” said Ms. Pai Panandiker. “LB-102 represents meaningful innovation in an area of high unmet need, and I look forward to working with the LB team to bring this important treatment to patients.”

Ms. Pai Panandiker holds a Master’s degree in Public Policy from the University of Chicago and a Bachelor of Arts from the University of Wisconsin–Madison.

About LB-102

LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition. LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. Additional expansion opportunities for LB-102 could include major depressive disorder (MDD), predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia.

About LB Pharmaceuticals

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102 and continuing advancement of LB-102 and the Company’s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts
Media: 
Michael Tattory
LifeSci Communications
Mtattory@lifescicomms.com

Investor Relations: 
Joyce Allaire 
LifeSci Advisors 
JAllaire@LifeSciAdvisors.com

Elite Dentistry Launches Comprehensive Laser Dentistry Services, Building on Strong Community Roots in Rancho Santa Margarita




Elite Dentistry Launches Comprehensive Laser Dentistry Services, Building on Strong Community Roots in Rancho Santa Margarita

Rancho Santa Margarita, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) — Elite Dentistry, a modern tech-forward dental practice led by Dr. Mehran Rastegar-Lari, is proud to announce the official launch of its comprehensive laser dentistry powered by Gemini EVO and Solea laser systems – two of the most advanced technologies in modern dental care. These services represent the next chapter in the clinic’s ongoing mission to provide precise, comfortable, and minimally invasive dental treatment within the Rancho Santa Margarita community.

This announcement follows the clinic’s Grand Opening and ribbon-cutting celebration with the Rancho Santa Margarita Chamber of Commerce on May 17, 2025, which marked the practice’s formal introduction to the community. Since then, Elite Dentistry has continued to grow its patient base and enhance its technology suite, reinforcing its commitment to innovation and comprehensive care.

“Our goal has always been to combine cutting-edge technology with a personalized, human-centered approach,” said Dr. Rastegar-Lari. “Laser dentistry allows us to elevate both precision and comfort, helping patients achieve healthier, more confident smiles with minimal discomfort or downtime.”

Advancing Care Through Modern Laser Technology
Elite Dentistry’s new Gemini EVO dual-wavelength soft-tissue laser and Solea all-tissue laser enables the clinic to perform a variety of restorative, cosmetic, and periodontal procedures with greater precision and comfort.

The Solea laser uses a computer-guided carbon-dioxide wavelength to vaporize tooth structure and soft tissue with better accuracy. It enables gentle cavity preparation, gum recontouring, and frenectomies without the vibration or heat of a traditional drill. The Gemini EVO system, on the other hand, provides enhanced soft-tissue management, including periodontal therapy and cosmetic contouring, using a dual-wave approach that adapts to each tissue type.

What Laser Dentistry Means for Patients and the Community
With Elite Dentistry’s advanced laser systems, patients can now experience gentler, more efficient care – right in Rancho Santa Margarita.

Laser dentistry not only enhances comfort and reduces anxiety, but also shortens recovery times, minimizes the need for anesthesia, and improves precision for both preventive and corrective procedures. This technology is especially beneficial for patients who experience dental anxiety, children who are nervous about traditional drills, and adults with complex treatments needs.

Residents can now experience procedures such as gum reshaping and oral lesion removal without the discomfort commonly associated with conventional techniques. The quiet, vibration-free process creates a more relaxing and approachable environment, encouraging patients to keep up with regular visits without traveling outside the city.

Patients who once delayed treatments due to fear or discomfort can now access a minimally invasive, stress-free option, leading to earlier interventions and better oral health.

“Rancho Santa Margarita deserves world-class care close to home,” said Dr. Rastegar-Lari. “These technologies represent our promise to stay at the forefront of modern dentistry, while making comfort and convenience our top priorities.”

Continuing to Grow in Rancho Santa Margarita
Located in the Plaza Antonio Shopping Center, Elite Dentistry offers easy access from Antonio Parkway and is surrounded by other popular shops and services, making it a convenient destination for families and working professionals alike.

Since its ribbon cutting earlier this year, the practice has steadily grown through patient referrals and community engagement. Residents have praised Elite Dentistry for its professionalism, warmth, and modern approach to care.

Reflecting on the journey since then, Dr. Rastegar-Lari shared, “Our grand opening was the beginning of something special. The support we received from the Chamber, our neighbors, and our patients gave us the foundation to keep growing. Launching our laser dentistry services is a continuation of that same vision – to bring world-class dental innovation right here to Rancho Santa Margarita.

To learn more about Elite Dentistry’s laser services and other suite of offerings, please visit https://elitedentistryrsm.com/.

About Elite Dentistry
Elite Dentistry of Rancho Santa Margarita provides comprehensive general, cosmetic, and restorative dental services in a modern, spa-inspired setting. Led by Dr. Mehran Rastegar-Lari, dentist in Rancho Santa Margarita with over 25 years of international experience, the practice offers advanced technologies including CEREC same-day crowns, CBCT 3D imaging, Gemini EVO and Solea laser systems, and soft-tissue lasers for minimally invasive care. Elite Dentistry is dedicated to making modern dental care accessible, comfortable, and educational, with multilingual service in English, Spanish, and Persian. The practice is conveniently located in the Plaza Antonio Shopping Center, easily accessible from Antonio Parkway in Rancho Santa Margarita, CA.

Media Contact
Company Name: Elite Dentistry
Contact Person: Amin Nassiri
Contact Number: (310) 592-6293
Email: amin@dentistnerds.com
Country: United States
Website: https://elitedentistryrsm.com/
Socials: https://www.instagram.com/elitedentistryrsm/

CONTACT: Media Contact
Company Name: Elite Dentistry
Contact Person: Amin Nassiri
Contact Number: (310) 592-6293
Email: amin@dentistnerds.com
Country: United States
Website: https://elitedentistryrsm.com/
Socials: https://www.instagram.com/elitedentistryrsm/

From Parliament Hill to Capitol Hill to the Brussels Bubble — Who’s the Cutest Pet?




From Parliament Hill to Capitol Hill to the Brussels Bubble — Who’s the Cutest Pet?

Global Cutest Pets Showdown Unites the Animal Health Industry in a Friendly (and Furry) Competition

OTTAWA, Ontario, Nov. 12, 2025 (GLOBE NEWSWIRE) — Three national and regional animal health associations are joining forces to announce the first annual Global Cutest Pets Showdown, bringing together pets and animal lovers from around the world in a contest to celebrate the bond between people and their animals.

The international showdown features the winners of three popular contests – Cutest Pets on Parliament Hill (Canada), Cutest Pets on Capitol Hill (United States), and Best Buddies in the Brussels Bubble (Europe) – in one global competition to determine, once and for all: Who’s the Cutest?

Organized by the Canadian Animal Health Institute (CAHI), the Animal Health Institute (AHI), and AnimalhealthEurope, the friendly rivalry aims to spotlight the shared passion for animal health, welfare, and companionship across continents.

“The Global Cutest Pets Showdown showcases how pets can transcend politics and borders, strengthening relationships and understanding across political aisles and ideological differences,” said Catherine Filejski, President of the Canadian Animal Health Institute. “On Parliament Hill, we’ve seen firsthand how our four-legged friends can bridge partisan divides and remind us that caring for animals is a shared priority, one that connects policymakers, industry, and the public alike. But Canadian pets are definitely the cutest, so elbows up Canada!”

Martha Scott Poindexter, President and CEO of the Animal Health Institute, added: “It’s hard to find agreement on anything in Washington these days, but the important role pets play in our lives brings everyone together. The Cutest Pets on Capitol Hill contest helps focus attention on the important role of keeping pets healthy, and we’re excited to take that message global in a friendly competition with our partners in Canada and Europe.”

From Brussels, Roxane Feller, Director General of AnimalhealthEurope, shared: “This global collaboration reflects our shared commitment to healthy animals and a healthy society. Whether in Europe, North America, or beyond, our pets remind us why the work we do in animal health truly matters.”

Participants and the public are encouraged to cast their votes for their favourite finalist through the contest website. The winning pet will be announced on December 9^th, the International Day of Veterinary Medicine, earning the ultimate bragging rights as the World’s Cutest Pet of 2025, and, more importantly, the hearts of animal lovers everywhere.

To vote and learn more about the contest, visit:

https://ahi.org/2025-global-cutest-pets-public-voting/

About the Canadian Animal Health Institute (CAHI)
Established in 1968, CAHI is the trusted, science-based voice of the Canadian animal health industry. Our members provide Canada’s veterinarians and animal owners with the veterinary medicines and tools necessary to maintain the health of our pets and food animal population. Healthier animals for a healthier Canada.

About the Animal Health Institute (AHI)
The Animal Health Institute (AHI) represents companies in the U.S. that make products to keep animals healthy, including drugs, vaccines, feed additives and diagnostics. Our members develop and make products that help pets live longer, healthier lives and contribute to safe food by keeping food animals healthy.

About AnimalhealthEurope
AnimalhealthEurope represents manufacturers of animal medicines, vaccines, and other health products across Europe, promoting a sustainable and responsible approach to animal health and welfare. Membership includes 14 of Europe’s leading manufacturers of animal medicines and 16 national associations in 20 countries.

Media Contact:
Eleanor Hawthorn        
Communications Manager
Canadian Animal Health Institute
ehawthorn@cahi-icsa.ca

Seoul National University Hospital Showcases Korea’s Next-Generation Medical Technologies at MEDICA 2025




Seoul National University Hospital Showcases Korea’s Next-Generation Medical Technologies at MEDICA 2025

Smart Ophthalmic, Dementia Care, and AI Musculoskeletal Solutions Take the Global Stage

SEOUL, South Korea, Nov. 12, 2025 (GLOBE NEWSWIRE) — Seoul National University Hospital (SNUH) is set to lead Korea’s participation at MEDICA 2025, the world’s largest medical trade fair, taking place this November in Düsseldorf, Germany.

In collaboration with three pioneering Korean companies — MICROT Inc., Emocog Inc., and Connecteve Co., Ltd. — SNUH will present a range of next-generation medical innovations that reflect Korea’s growing leadership in global healthcare technology.

This joint participation underscores Korea’s commitment to advancing medical excellence through smart ophthalmic devices, digital dementia solutions, and AI-powered diagnostic systems.

MICROT Inc.
MICROT develops innovative ophthalmic technologies designed to improve the safety and effectiveness of glaucoma treatment. Its next-generation A-stream Glaucoma Shunt provides stable intraocular pressure (IOP) control through simplified surgical procedures with minimal hypotony risk. Demonstrating a six-month success rate of 93.9%, the device is redefining the global standard for glaucoma care.

https://kr.microtinc.com/en/index.php

Emocog Inc.
Emocog is a bio-digital healthcare company dedicated to transforming the entire dementia care continuum — from prevention and diagnosis to treatment. By leveraging digital transformation, the company aims to overcome the limitations of traditional dementia management, helping individuals maintain cognitive health and independent living for longer.

https://www.emocog.com/en

Connecteve Co., Ltd.
Connecteve specializes in AI-driven musculoskeletal diagnostic solutions that enhance precision and efficiency in clinical practice. Its proprietary AI systems assist healthcare professionals in making accurate diagnostic decisions and optimizing musculoskeletal care workflows within hospitals and clinics.

https://connecteve.com/

The joint showcase at MEDICA 2025 will serve as a platform to highlight Korea’s excellence in medical technology and foster international collaboration across the global healthcare sector.

Visitors can meet the Korean delegation at Hall 9, Booth B29, Messe Düsseldorf Exhibition Center.

Contact: jhl@snuh.org / +82-2-2072-0277

Seoul National University Hospital

This initiative was supported by the Bio & Medical Technology Development Program (Global Entrepreneurship Support for Start-up driven by SNUH Consilience Platform, GREAT), funded by the Korean government (MSIT) through the National Research Foundation of Korea (NRF). (Project No. RS-2024-00508402)

Or
Amy Kim
Medical PR Agency, InterAd Korea
Email: contact@interad.com

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years




DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

Châtillon, France, November 11, 2025

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN^® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

• Company remains on track for VITESSE topline data in Q4 of this year

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company’s Phase 3 VITESSE clinical trial of the VIASKIN^® Peanut patch in peanut allergic children aged 4-7 years.

With the completion of the double-blind, placebo-controlled treatment phase of the study, DBV remains on track to announce topline data from VITESSE in the fourth quarter of this year.

“Last patient last visit represents a very important milestone for DBV, as it brings us one step closer to the potential of bringing this treatment option to peanut allergic children, their physicians and caregivers, if approved,” stated Daniel Tassé, Chief Executive Officer of DBV Technologies. “We’re grateful to the investigators, internal teams, and most importantly patients and caregivers for their time and commitment to this study. We look forward to sharing topline results this quarter.”

The VITESSE Phase 3 trial in peanut-allergic children ages 4 – 7 is a 12-month study evaluating the efficacy and safety of the VIASKIN® Peanut patch in 654 subjects (randomized 2:1), representing individuals across 86 sites in the U.S., Canada, Europe, the UK, and Australia. VITESSE is currently the largest treatment intervention study in peanut allergy.

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN^® Peanut patch and EPIT, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations regarding initiation of the confirmatory study, plans and expectations with respect to the submission of BLAs to FDA, anticipated support for the BLA submission, , and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• Version PDF